Desma
Laboratorio Farmaceutico S.I.T. is an Italian pharmaceutical group with almost 100 years of history, present in over 70 countries. The company manufactures and markets therapeutic solutions made in Italy, with strategic locations in Europe, and is committed to high standards of quality, safety, and efficacy. It values people, excellence, and long-lasting partnerships, continuously working to develop new therapeutic solutions and maintain therapeutic continuity for patients worldwide.
Industries
Nr. of Employees
small (1-50)
Products
Pharmaceutical and healthcare product portfolio
A portfolio including ethical (prescription) drugs, OTC drugs, food supplements, cosmetics and medical devices across multiple therapeutic areas and dosage forms.
Pharmaceutical and healthcare product portfolio
A portfolio including ethical (prescription) drugs, OTC drugs, food supplements, cosmetics and medical devices across multiple therapeutic areas and dosage forms.
Services
On-site manufacture and primary/secondary packaging for oral liquids, tablets, capsules, ointments, gels, sprays and suppositories; includes serialization and batch release testing.
Channels and processes to receive and handle adverse event reports, including a reporting form, dedicated email and phone contact.
Support for international distributors including marketing coordination, communication materials and logistics support to adapt products to local markets.
Nationwide medical sales representative network for information updates and engagement with general practitioners and medical specialists.
On-site manufacture and primary/secondary packaging for oral liquids, tablets, capsules, ointments, gels, sprays and suppositories; includes serialization and batch release testing.
Channels and processes to receive and handle adverse event reports, including a reporting form, dedicated email and phone contact.
Support for international distributors including marketing coordination, communication materials and logistics support to adapt products to local markets.
Nationwide medical sales representative network for information updates and engagement with general practitioners and medical specialists.
Expertise Areas
- Pharmaceutical formulation and dosage form manufacturing
- Non-sterile liquid and suppository production
- Medical device manufacturing
- Quality control (microbiological and chemical)
Key Technologies
- Formulation and manufacturing of oral liquids, solids and semi-solids
- Non-sterile suppository production
- Serialization (GS1 and RU protocols)
- Microbiological testing
News & Updates
The acquisition of DINTOINA confirms our will to grow our Italian portfolio in CNS area with essential and well know products and to maintain and assure, to patients and HCP's, the therapeutic continuity
Centellase has a new strategic visual and a new claim: “Ci prendiamo cura della tua bellezza” (We take care of your beauty).
SIT Group is pleased to announce the acquisition of established product SULMETIN from Sanofi, as a result of the agreement signed on November 8, 2022.
The acquisition of DINTOINA confirms our will to grow our Italian portfolio in CNS area with essential and well know products and to maintain and assure, to patients and HCP's, the therapeutic continuity
Centellase has a new strategic visual and a new claim: “Ci prendiamo cura della tua bellezza” (We take care of your beauty).
SIT Group is pleased to announce the acquisition of established product SULMETIN from Sanofi, as a result of the agreement signed on November 8, 2022.